Forte Biosciences (FBRX): OrbiMed entities disclose 7.7% aggregate ownership stake

Rhea-AI Filing Summary

Forte Biosciences, Inc. has an updated ownership report from OrbiMed-related entities. OrbiMed Advisors LLC reports beneficial ownership of 1,264,980 shares of common stock, representing 6.2% of the class. OrbiMed Capital GP IX LLC reports 1,041,742 shares, or 5.1%, and OrbiMed Capital LLC reports 312,725 shares, or 1.5%.

OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC report shared voting and dispositive power over their positions, while OrbiMed Capital LLC reports sole voting and dispositive power over 312,725 shares. In the aggregate, the reporting persons hold 7.7% of Forte Biosciences’ common stock on behalf of other persons who have rights to dividends or sale proceeds. Investment and voting power is exercised through a management committee of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership.

Key Figures

OrbiMed Advisors LLC beneficial ownership: 1,264,980 shares OrbiMed Advisors LLC percent of class: 6.2% OrbiMed Capital GP IX LLC beneficial ownership: 1,041,742 shares +4 more

7 metrics

OrbiMed Advisors LLC beneficial ownership 1,264,980 shares Beneficially owned Forte Biosciences common stock; 6.2% of class

OrbiMed Advisors LLC percent of class 6.2% Percentage of Forte Biosciences common stock class

OrbiMed Capital GP IX LLC beneficial ownership 1,041,742 shares Beneficially owned Forte Biosciences common stock; 5.1% of class

OrbiMed Capital GP IX LLC percent of class 5.1% Percentage of Forte Biosciences common stock class

OrbiMed Capital LLC beneficial ownership 312,725 shares Beneficially owned Forte Biosciences common stock; 1.5% of class

OrbiMed Capital LLC percent of class 1.5% Percentage of Forte Biosciences common stock class

Aggregate ownership on behalf of others 7.7% Aggregate Forte Biosciences common stock held by reporting persons on behalf of other persons

Key Terms

beneficially owned, shared voting power, dispositive power, percent of class, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: OrbiMed Advisors LLC: 1,264,980"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 1,264,980.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

dispositive power financial

"Shared Dispositive Power 1,264,980.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

percent of class financial

"Percent of class: OrbiMed Advisors LLC: 6.2%"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

Investment Company Act of 1940 regulatory

"investment company registered under the Investment Company Act of 1940"

A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.

FAQ

How much of Forte Biosciences (FBRX) stock does OrbiMed Advisors LLC beneficially own?

OrbiMed Advisors LLC beneficially owns 1,264,980 shares of Forte Biosciences common stock, representing 6.2% of the outstanding class. These shares are held with shared voting and dispositive power as disclosed in the Schedule 13G/A amendment.

What percentage of Forte Biosciences (FBRX) does OrbiMed Capital GP IX LLC hold?

OrbiMed Capital GP IX LLC beneficially owns 1,041,742 shares of Forte Biosciences common stock, equal to 5.1% of the class. It reports shared voting and dispositive power over these shares under the Schedule 13G/A filing.

What are the holdings and control rights of OrbiMed Capital LLC in Forte Biosciences (FBRX)?

OrbiMed Capital LLC holds 312,725 shares of Forte Biosciences common stock, or 1.5% of the class. It reports sole voting and sole dispositive power over these shares, distinguishing its control from the other OrbiMed entities.

What is the aggregate ownership of Forte Biosciences (FBRX) reported by the OrbiMed entities?

The reporting persons state they hold 7.7% of Forte Biosciences’ common stock in the aggregate on behalf of other persons. Those persons have the right to receive dividends or sale proceeds from the shares, as described in the ownership item.

Who exercises investment and voting power over OrbiMed’s Forte Biosciences (FBRX) shares?

Investment and voting power over the Forte Biosciences shares is exercised by a management committee of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu. Each member disclaims beneficial ownership of the reported shares in the Schedule 13G/A.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 05:27 PM Accepted by SEC EDGAR 08/14/2026 - 05:26 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Forte Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

34962G208

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 34962G208

1

Names of Reporting Persons

ORBIMED ADVISORS LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,264,980.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,264,980.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,264,980.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 34962G208

1

Names of Reporting Persons

OrbiMed Capital GP IX LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,041,742.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,041,742.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,041,742.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 34962G208

1

Names of Reporting Persons

ORBIMED CAPITAL LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 312,725.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 312,725.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

312,725.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Forte Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 3060 Pegasus Park Dr., Building 6, Dallas, Texas 75247
Item 2.
(a)	Name of person filing: OrbiMed Advisors LLC OrbiMed Capital GP IX LLC OrbiMed Capital LLC
(b)	Address or principal business office or, if none, residence: 601 Lexington Avenue, 54th Floor New York, NY 10022
(c)	Citizenship: Please refer to Item 4 on each cover sheet for each filing person.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 34962G208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: OrbiMed Advisors LLC: 1,264,980 OrbiMed Capital GP IX LLC: 1,041,742 OrbiMed Capital LLC: 312,725
(b)	Percent of class: OrbiMed Advisors LLC: 6.2% OrbiMed Capital GP IX LLC: 5.1% OrbiMed Capital LLC: 1.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: OrbiMed Advisors LLC: 0 OrbiMed Capital GP IX LLC: 0 OrbiMed Capital LLC: 312,725
	(ii) Shared power to vote or to direct the vote: OrbiMed Advisors LLC: 1,264,980 OrbiMed Capital GP IX LLC: 1,041,742 OrbiMed Capital LLC: 0
	(iii) Sole power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 0 OrbiMed Capital GP IX LLC: 0 OrbiMed Capital LLC: 312,725
	(iv) Shared power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 1,264,980 OrbiMed Capital GP IX LLC: 1,041,742 OrbiMed Capital LLC: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Reporting Persons hold 7.7% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ORBIMED ADVISORS LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon/Member
Date:	08/14/2026

OrbiMed Capital GP IX LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon/Member of OrbiMed Advisors LLC
Date:	08/14/2026

ORBIMED CAPITAL LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon/Member
Date:	08/14/2026